Works matching DE "FINGOLIMOD"

Results: 669

In vitro investigation of the toxicological mechanisms of Fingolimod (S)-phosphate in HEPG2 cells Open Access.

Published in:

Toxicology Research, 2025, v. 14, n. 3, p. 1, doi. 10.1093/toxres/tfaf064

By:

Bilgehan, Ayşenur;
Şeker, Zehra;
Qaoud, Mohammed T;
Özhan, Gül

Publication type:

Article

Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).

Published in:

Journal of Neuro-Oncology, 2019, v. 144, n. 2, p. 303, doi. 10.1007/s11060-019-03227-7

By:

Hainsworth, John D.;
Becker, Kevin P.;
Mekhail, Tarek;
Chowdhary, Sajeel A.;
Eakle, Janice Faulkner;
Wright, David;
Langdon, Robert M.;
Yost, Kathleen J.;
Padula, Gilbert Darin Anthony;
West-Osterfield, Kimberly;
Scarberry, Meredith;
Shaifer, Candice A.;
Shastry, Mythili;
Burris III, Howard A.;
Shih, Kent

Publication type:

Article

Fingolimod attenuates ovalbumin‐induced airway inflammation via inhibiting MAPK/ERK signaling in mice.

Published in:

Journal of Biochemical & Molecular Toxicology, 2023, v. 37, n. 3, p. 1, doi. 10.1002/jbt.23266

By:

Makled, Mirhan N.;
El‐Sheakh, Ahmed R.

Publication type:

Article

Antioxidative effects of silymarin on the reduction of liver complications of fingolimod in patients with relapsing–remitting multiple sclerosis: A clinical trial study.

Published in:

Journal of Biochemical & Molecular Toxicology, 2021, v. 35, n. 8, p. 1, doi. 10.1002/jbt.22800

By:

Ghiasian, Masoud;
Nafisi, Hamid;
Ranjbar, Akram;
Mohammadi, Younes;
Ataei, Sara

Publication type:

Article

Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review.

Published in:

Current Journal of Neurology, 2023, v. 22, n. 2, p. 110, doi. 10.18502/cjn.v22i2.13339

By:

Ghadiri, Fereshteh;
Mirmosayyeb, Omid;
Sahraian, Mohammad Ali;
Moghadasi, Abdorreza Naser;
Ghajarzadeh, Mahsa

Publication type:

Article

Cure of Alzheimer's Dementia Requires Addressing All of the Affected Brain Cell Types.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 5, p. 2049, doi. 10.3390/jcm12052049

By:

Fessel, Jeffrey

Publication type:

Article

Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series.

Published in:

2022

By:

Abbadessa, Gianmarco;
Maida, Elisabetta;
Miele, Giuseppina;
Bile, Floriana;
Lavorgna, Luigi;
Bonavita, Simona

Publication type:

Case Study

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study.

Published in:

Journal of Clinical Medicine, 2022, v. 11, n. 13, p. 3584, doi. 10.3390/jcm11133584

By:

Hernández-Preciado, Martha Rocio;
Marquez-Pedroza, Jazmin;
Sánchez-Rosales, Nayeli Alejandra;
García-Rivera, José de Jesús;
Kobayashi-Gutiérrez, Antonio;
Torres-Mendoza, Blanca Miriam;
Chavarría-Avila, Efraín;
Montaño-Serrano, Raúl Alejandro;
Cortes-Enriquez, Fernando;
Mireles-Ramírez, Mario Alberto

Publication type:

Article

Differential Expression of the Sphingolipid Pathway Is Associated with Sensitivity to the PP2A Activator FTY720 in Colorectal Cancer Cell Lines.

Published in:

Journal of Clinical Medicine, 2021, v. 10, n. 21, p. 4999, doi. 10.3390/jcm10214999

By:

Sciberras, Peter;
Grech, Laura;
Grech, Godfrey

Publication type:

Article

Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients.

Published in:

Journal of Clinical Medicine, 2021, v. 10, n. 9, p. 1830, doi. 10.3390/jcm10091830

By:

Jamroz-Wiśniewska, Anna;
Zajdel, Radosław;
Słowik, Agnieszka;
Marona, Monika;
Wnuk, Marcin;
Adamczyk-Sowa, Monika;
Adamczyk, Bożena;
Lasek-Bal, Anetta;
Puz, Przemysław;
Stęposz, Arkadiusz;
Krzystanek, Ewa;
Patalong-Ogiewa, Maja;
Pokryszko-Dragan, Anna;
Budrewicz, Sławomir;
Koziarska, Dorota;
Karbicka, Anna;
Wawrzyniak, Sławomir;
Fryze, Waldemar;
Furtak-Niczyporuk, Marzena;
Rejdak, Konrad

Publication type:

Article

Inhibition of Human Neutrophil Functions In Vitro by Multiple Sclerosis Disease-Modifying Therapies.

Published in:

Journal of Clinical Medicine, 2020, v. 9, n. 11, p. 3542, doi. 10.3390/jcm9113542

By:

Scutera, Sara;
Musso, Tiziana;
Cavalla, Paola;
Piersigilli, Giorgia;
Sparti, Rosaria;
Comini, Sara;
Vercellino, Marco;
Cuffini, Anna Maria;
Banche, Giuliana;
Allizond, Valeria

Publication type:

Article

A randomized, open-label study assessing the bioequivalence of two formulations of Fingolimod 0.5 mg in healthy subjects.

Published in:

AAPS Open, 2018, v. 4, n. 1, p. 0, doi. 10.1186/s41120-018-0023-3

By:

Tanguay, Mario;
Fröhlich, Thomas;
Drouin, Mathieu;
Beuerle, Gerald

Publication type:

Article

FTY720 Attenuates LPS-Induced Inflammatory Bone Loss by Inhibiting Osteoclastogenesis via the NF-κB and HDAC4/ATF Pathways.

Published in:

Journal of Immunology Research, 2023, p. 1, doi. 10.1155/2023/8571649

By:

Chen, Chongwei;
Zong, Sujing;
Wang, Zhenyu;
Yang, Ruijia;
Guo, Yanjing;
Wang, Yunfei;
Chen, Xinping;
Li, Yue;
Wang, Shaowei

Publication type:

Article

Selenium nanoparticles coated with pH responsive silk fibroin complex for fingolimod release and enhanced targeting in thyroid cancer.

Published in:

Artificial Cells, Nanomedicine & Biotechnology, 2021, v. 49, n. 1, p. 83, doi. 10.1080/21691401.2021.1871620

By:

Zou, Xiangcai;
Jiang, Zhipeng;
Li, Liang;
Huang, Zonghai

Publication type:

Article

Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.

Published in:

Scientific Reports, 2014, p. 1, doi. 10.1038/srep05051

By:

Sheridan, Graham K.;
Dev, Kumlesh K.

Publication type:

Article

Sensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis.

Published in:

Iranian Journal of Otorhinolaryngology, 2020, v. 32, n. 4, p. 249, doi. 10.22038/ijorl.2020.40858.2334

By:

Moghadasi, Abdoreza Naser;
Poursadeghfard, Maryam;
Kazemi, Tayebeh;
Hosseini, Samaneh

Publication type:

Article

Bioequivalence Study of 2 Capsule Formulations of Fingolimod 0.5 mg Assessing Both Parent Drug and Active Metabolite in New Zealand Healthy Subjects (Truncated Design).

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 610, doi. 10.1002/cpdd.813

By:

Hung, Noelyn Anne;
Costa, Fernando Guillermo;
Hung, Cheung‐Tak;
Rosenberg, Mónica Esther

Publication type:

Article

Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2018, v. 7, n. 6, p. 575, doi. 10.1002/cpdd.459

By:

David, Olivier J.;
Behrje, Rhett;
Pal, Parasar;
Hara, Hisanori;
Lates, Christian D.;
Schmouder, Robert

Publication type:

Article

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod.

Published in:

Clinical Pharmacology in Drug Development, 2018, v. 7, n. 2, p. 217, doi. 10.1002/cpdd.424

By:

David, Olivier J.;
Berwick, Amy;
Pezous, Nicole;
Lang, Michael;
Tiel‐Wilck, Klaus;
Ziemssen, Tjalf;
Li, Peng;
Hara, Hisanori;
Schmouder, Robert

Publication type:

Article

Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) Attenuates Myocardial Fibrosis in Post-heterotopic Heart Transplantation.

Published in:

Frontiers in Pharmacology, 2017, p. 1, doi. 10.3389/fphar.2017.00645

By:

Ahmed, Naseer;
Linardi, Daniele;
Muhammad, Nazeer;
Chiamulera, Cristiano;
Fumagalli, Guido;
Biagio, Livio San;
Gebrie, Mebratu A.;
Aslam, Muhammad;
Luciani, Giovanni Battista;
Faggian, Giuseppe;
Rungatscher, Alessio

Publication type:

Article

Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder.

Published in:

Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1115120

By:

Wei Lin;
Chung-Hsing Chou;
Fu-Chi Yang;
Chia-Kuang Tsai;
Yu-Kai Lin;
Yueh-Feng Sung

Publication type:

Article

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod.

Published in:

Case Reports in Neurological Medicine, 2016, p. 1, doi. 10.1155/2016/5876798

By:

Sinnecker, Tim;
Othman, Jalal;
Kühl, Marc;
Metz, Imke;
Niendorf, Thoralf;
Kunkel, Annett;
Paul, Friedemann;
Wuerfel, Jens;
Faiss, Juergen

Publication type:

Article

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation.

Published in:

Case Reports in Neurological Medicine, 2014, p. 1, doi. 10.1155/2014/307872

By:

Killestein, J.;
Vennegoor, A.;
van Golde, A. E. L.;
Bourez, R. L. J. H.;
Wijlens, M. L. B.;
Wattjes, M. P.

Publication type:

Article

Intermittent Atrioventricular Block following Fingolimod Initiation.

Published in:

Case Reports in Neurological Medicine, 2014, p. 1, doi. 10.1155/2014/191305

By:

Gialafos, E.;
Gerakoulis, S.;
Grigoriou, A.;
Haina, V.;
Kilidireas, C.;
Stamboulis, E.;
Andreadou, E.

Publication type:

Article

Fingolimod and melanoma risk: is there sufficient evidence?

Published in:

Clinical & Experimental Dermatology, 2017, v. 42, n. 4, p. 427, doi. 10.1111/ced.13066

By:

Filoni, A.;
Lospalluti, L.;
Giudice, G.;
Bonamonte, D.;
Vestita, M.

Publication type:

Article

Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis.

Published in:

Clinical & Experimental Dermatology, 2016, v. 41, n. 4, p. 433, doi. 10.1111/ced.12770

By:

Haebich, G.;
Mughal, A.;
Tofazzal, N.

Publication type:

Article

Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal.

Published in:

2021

By:

Koska, Valeria;
Förster, Moritz;
Brouzou, Katja;
Arat, Ercan;
Albrecht, Philipp;
Aktas, Orhan;
Küry, Patrick;
Meuth, Sven G.;
Kremer, David

Publication type:

Case Study

Synergistic effects of vemurafenib and fingolimod (FTY720) in vemurafenib-resistant melanoma cell lines.

Published in:

Molecular Medicine Reports, 2018, v. 18, n. 6, p. 5151, doi. 10.3892/mmr.2018.9537

By:

Takahashi, Tomoko;
Abe, Naoko;
Kanoh, Hiroyuki;
Banno, Yoshiko;
Seishima, Mariko

Publication type:

Article

Treatment of experimental autoimmune myasthenia gravis rats with FTY720 and its effect on Th1/Th2 cells.

Published in:

Molecular Medicine Reports, 2018, v. 17, n. 5, p. 7409, doi. 10.3892/mmr.2018.8768

By:

Huang, Jiankang;
Zhang, Ting;
Wang, Hongmei;
Zhao, Yuwu

Publication type:

Article

Synergistic protective effect of FTY720 and vitamin E against simulated cerebral ischemia in vitro.

Published in:

Molecular Medicine Reports, 2017, v. 16, n. 1, p. 396, doi. 10.3892/mmr.2017.6572

By:

Xin Pang;
Xuening Hou

Publication type:

Article

FTY720 enhances osteogenic differentiation of bone marrow mesenchymal stem cells in ovariectomized rats.

Published in:

Molecular Medicine Reports, 2016, v. 14, n. 1, p. 927, doi. 10.3892/mmr.2016.5342

By:

CHUANG HUANG;
RUI LING;
FEI-JIANG LI;
ER-CUI LI;
QI-KE HUANG;
BAO-GANG LIU;
YIN DING;
SI-WEI YOU

Publication type:

Article

MS medication may be associated with macula edema.

Published in:

Optometry Times, 2014, v. 6, n. 6, p. 19

By:

Ferrucci, Steven;
Shandrick, Alyssa

Publication type:

Article

Preclinical evaluation of the immunomodulatory lymphocyte trafficking drug FTY720 for HIV prevention in the female genital mucosa of macaques.

Published in:

Journal of Medical Primatology, 2014, v. 43, n. 5, p. 370, doi. 10.1111/jmp.12120

By:

Morris, Monica;
Aubert, Rachael D.;
Butler, Katherine;
Henning, Tara;
Mitchell, James;
Jenkins, Leecresia;
Garber, David;
McNicholl, Janet;
Kersh, Ellen N.

Publication type:

Article

CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients.

Published in:

2022

By:

Karaaslan, Zerrin;
Kurtuncu, Murat;
Akcay, Halil İbrahim;
Gunduz, Tuncay;
Altunrende, Burcu;
Turkoglu, Recai;
Eraksoy, Mefkure;
Ulusoy, Canan;
Yilmaz, Vuslat;
Tüzün, Erdem

Publication type:

Letter

Long-Term Effectiveness of Fingolimod for Multiple Sclerosis in a Real-World Clinical Setting.

Published in:

European Neurology, 2021, v. 84, n. 3, p. 200, doi. 10.1159/000514828

By:

Uzunköprü, Cihat;
Beckmann, Yesim;
Türe, Sabiha

Publication type:

Article

Anxiety and Coping Strategy Changes in Multiple Sclerosis Patients Initiating Fingolimod: The GRACE Prospective Study.

Published in:

European Neurology, 2017, v. 77, n. 1/2, p. 47, doi. 10.1159/000451077

By:

Moreau, Thibault;
Bungener, Catherine;
Heinzlef, Olivier;
Suchet, Laurent;
Borgel, Florent;
Bourdeix, Isabelle;
Meite, Mohamed;
Rerat, Karin;
Chouette, Isabelle

Publication type:

Article

Description of the Characteristics of Multiple Sclerosis Patients in the Region of Valencia (Spain) Who Requested Treatment with Disease-Modifying Drugs during the 2005-2014 Decade.

Published in:

European Neurology, 2016, v. 75, n. 5/6, p. 274, doi. 10.1159/000446580

By:

Ribes García, Sara;
Gómez-Pajares, Fernando;
albelda Puig, Carmen;
García Herrera, José Luis;
Casanova Estruch, Bonaventura

Publication type:

Article

Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab.

Published in:

European Neurology, 2015, v. 73, n. 1/2, p. 57, doi. 10.1159/000365968

By:

Bianco, assunta;
Patanella, agata Katia;
Nociti, Viviana;
Marti, alessandro;
Frisullo, Giovanni;
Plantone, Domenico;
De Fino, Chiara;
Fetta, anna;
Batocchi, anna Paola;
Rossini, Paolo Maria;
Mirabella, Massimiliano

Publication type:

Article

Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis? A Clinical Practice Observational Study.

Published in:

European Neurology, 2014, v. 72, n. 3/4, p. 173, doi. 10.1159/000361044

By:

Gajofatto, alberto;
Bianchi, Maria Rachele;
Deotto, Luciano;
Benedetti, Maria Donata

Publication type:

Article

Involvement of vacuolar H+- ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720.

Published in:

Pigment Cell & Melanoma Research, 2015, v. 28, n. 2, p. 171, doi. 10.1111/pcmr.12326

By:

Tay, Kwang Hong;
Liu, Xiaoying;
Chi, Mengna;
Jin, Lei;
Jiang, Chen Chen;
Guo, Su Tang;
Verrills, Nicole M.;
Tseng, Hsin ‐ Yi;
Zhang, Xu Dong

Publication type:

Article

Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model.

Published in:

PLoS ONE, 2022, v. 17, n. 12, p. 1, doi. 10.1371/journal.pone.0278488

By:

Najarzadegan, Niloofar;
Madani, Mahboobeh;
Etemadifar, Masoud;
Sedaghat, Nahad

Publication type:

Article

The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary.

Published in:

PLoS ONE, 2022, v. 17, n. 4, p. 1, doi. 10.1371/journal.pone.0267346

By:

Biernacki, Tamás;
Sandi, Dániel;
Füvesi, Judit;
Fricska-Nagy, Zsanett;
Kincses, Tamás Zsigmond;
Ács, Péter;
Rózsa, Csilla;
Dobos, Enikő;
Cseh, Botond;
Horváth, László;
Nagy, Zsuzsanna;
Csányi, Attila;
Kovács, Krisztina;
Csépány, Tünde;
Vécsei, László;
Bencsik, Krisztina

Publication type:

Article

Ocrelizumab experience in treatment-resistant warts associated with Fingolimod: A case report.

Published in:

Neurology Asia, 2024, v. 29, n. 2, p. 489, doi. 10.54029/2024kps

By:

Uca, Ali Ulvi

Publication type:

Article

A2 B Adenosine Receptors and Sphingosine 1-Phosphate Signaling Cross-Talk in Oligodendrogliogenesis.

Published in:

Frontiers in Neuroscience, 2021, v. 15, p. 1, doi. 10.3389/fnins.2021.677988

By:

Coppi, Elisabetta;
Cencetti, Francesca;
Cherchi, Federica;
Venturini, Martina;
Donati, Chiara;
Bruni, Paola;
Pedata, Felicita;
Pugliese, Anna Maria

Publication type:

Article

Neuroprotective Effects of Fingolimod Supplement on the Retina and Optic Nerve in the Mouse Model of Experimental Autoimmune Encephalomyelitis.

Published in:

Frontiers in Neuroscience, 2021, v. 15, p. N.PAG, doi. 10.3389/fnins.2021.663541

By:

Yang, Tao;
Zha, Zheng;
Yang, Xiao;
Kang, YueZhi;
Wang, Xin;
Tong, Yanping;
Zhao, XueSong;
Wang, Lei;
Fan, YongPing

Publication type:

Article

Fingolimod Inhibits Inflammation but Exacerbates Brain Edema in the Acute Phases of Cerebral Ischemia in Diabetic Mice.

Published in:

Frontiers in Neuroscience, 2020, v. 14, p. N.PAG, doi. 10.3389/fnins.2020.00842

By:

Li, Wanlu;
He, Tingting;
Jiang, Lu;
Shi, Rubing;
Song, Yaying;
Mamtilahun, Muyassar;
Ma, Yuanyuan;
Zhang, Zhijun;
Tang, Yaohui;
Yang, Guo-Yuan;
Wang, Yongting

Publication type:

Article

Fingolimod in children with Rett syndrome: the FINGORETT study.

Published in:

2021

By:

Naegelin, Yvonne;
Kuhle, Jens;
Schädelin, Sabine;
Datta, Alexandre N.;
Magon, Stefano;
Amann, Michael;
Barro, Christian;
Ramelli, Gian Paolo;
Heesom, Kate;
Barde, Yves-Alain;
Weber, Peter;
Kappos, Ludwig

Publication type:

journal article

FTY720 Attenuates Angiotensin II-Induced Podocyte Damage via Inhibiting Inflammatory Cytokines.

Published in:

Mediators of Inflammation, 2017, p. 1, doi. 10.1155/2017/3701385

By:

Su, Ke;
Zeng, Ping;
Liang, Wei;
Luo, Zhengyu;
Wang, Yiman;
Lv, Xifeng;
Han, Qi;
Yan, Miao;
Chen, Cheng

Publication type:

Article

AV block II in a toddler after ingestion of a single tablet fingolimod.

Published in:

Clinical Toxicology (15563650), 2014, v. 52, n. 6, p. 644, doi. 10.3109/15563650.2014.927478

By:

Höjer, Jonas;
Olsson, Eva

Publication type:

Article

Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?

Published in:

Epilepsia (Series 4), 2020, v. 61, n. 3, p. 359, doi. 10.1111/epi.16450

By:

Klein, Pavel;
Friedman, Alon;
Hameed, Mustafa Q.;
Kaminski, Rafal M.;
Bar‐Klein, Guy;
Klitgaard, Henrik;
Koepp, Mathias;
Jozwiak, Sergiusz;
Prince, David A.;
Rotenberg, Alexander;
Twyman, Roy;
Vezzani, Annamaria;
Wong, Michael;
Löscher, Wolfgang

Publication type:

Article